THCP, a new cannabinoid 30 times «more potent than THC» (but extremely rare)

A recent study published in Nature reveals the discovery of two previously unknown cannabinoids, called THCP and CBDP.

When tested on mice, the researchers discovered that Δ9-THCP, for tetrahydrocannabiphorol, showed »an affinity for the CB1 receptor more than thirty times higher than that reported for THC».

Although researchers have so far identified about 150 cannabinoids in cannabis, the majority of studies have focused on the two present in greatest concentration: the CBD and THC. The emergence of equally strong or stronger cannabinoids will undoubtedly lead to further studies, particularly on medical effects of cannabis.

«A number of clinical trials and a growing number of publications provide tangible evidence of the pharmacological potential of cannabis and cannabinoids on a wide range of disorders from sleep to anxiety, multiple sclerosis, autism and neuropathic pain,» the researchers said. «In particular, being the most potent psychotropic cannabinoid, the THC is the main objective of these studies.»

«THCP has an even higher binding affinity for the CB1 receptor and greater cannabimimetic activity than THC itself.»

Say Hello to a new Natural Cannabinoid named THCP.

More potent than THC.
Can we just grow hemp with gobs of THCP?https://t.co/SfVQ9EGw72 pic.twitter.com/LVD8TQnePW

- Kevin McKernan (@Kevin_McKernan) December 30, 2019

L’study was performed on an Italian variety, FM2, sourced from the Italian army and measured at 5.6% CBD and 3.9% THC. Ethanol extraction recovered 243µg/g CBDP and 29µg/g THCP.

The discovery of THCP could also help explain the specific pharmacological properties of certain cannabis varieties that previously could not be attributed to the presence of THC alone, the researchers said.

«In our opinion, this compound should be included in the list of main phytocannabinoids to be determined for a proper evaluation of the pharmacological effect of cannabis extracts administered to patients.»

As for CBDP, the researchers stated that the cannabinoid's low capacity to bind to CB1 or CB2 receptors made it a low priority to explore its cannabimimetic activity.